department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Imjudo · pharmadog

pharmadog
drugs
Imjudo

drug · antibody

patient view →

tremelimumab

Phase 3updated 2mo ago

by $AZN ASTRAZENECA PLC🔗 ChEMBL

Phase 3

community read0 votes

Antibody drug with a maximum clinical stage of Approval (across all indications), with 3 approved and 28 investigational indications.

indications

indications

NSCLC

targets

Cytotoxic T-lymphocyte protein 4

all catalysts(1)

phase 1 2 completion · 1

News(0)

no news has mentioned this drug yet

brand

Imjudo

trade names

Imjudo, Tremelimumab astrazeneca

generic

tremelimumab-actl

MOA

Cytotoxic T-lymphocyte protein 4 inhibitor

indication

Small-Cell Lung Cancer

phase

phase_3

phase 1 2 completion

Amsterdam UMC — tremelimumab (Phase I/II Trial Completion)

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Data sources

ClinicalTrials.gov · OpenTargets

last refreshed 1h ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

🐶 often sniffed alongside

top 4

tagOncology2 co-mentions · 1 sources
tagNSCLC2 co-mentions · 1 sources
companyAmsterdam UMC1 co-mentions · 1 sources
tagPulmonology1 co-mentions · 1 sources

Trials studying tremelimumab

phase2A Phase II Study of Durvalumab Treatment - Substudy A: In Patients Who Discontinued Prior Checkpoint Therapy Due to Immune Related Toxicity - Substudy B: For Continued Treatment (+/- Tremelimumab) of Patients Previously Enrolled to Completed CCTG Studiesrecruitingn=60
phase2A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular Carcinomaactive not recruitingn=433
phase2Radiation Therapy and Durvalumab With or Without Tremelimumab in Treating Participants With Unresectable, Locally Advanced, or Metastatic Bladder Canceractive not recruitingn=13
phase3Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinomarecruitingn=1,220
phase1Targeting Driver Oncogenes With a Peptide Vaccine Plus Durvalumab and Tremelimumab for Patients With Biliary Tract Cancers (BTC)recruitingn=25
phase2Durvalumab (MEDI4736) and Tremelimumab and Radiation Therapy in Hepatocellular Carcinoma and Biliary Tract Canceractive not recruitingn=37
phase3Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE)active not recruitingn=953
phase2Evaluation of RBS2418 in Combination With Tremelimumab Plus Durvalumab in Participants With Advanced Unresectable Hepatocellular Carcinomarecruitingn=220

more trials →